Radko Komers
Travere Therapeutics · Travere Therapeutics, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Radko Komers as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:16 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07219121 · Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisTravere Therapeutics, Inc. · active not recruiting · Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis · study director
- Ph2NCT05856760 · A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANTravere Therapeutics, Inc. · completed · Immunoglobulin A Nephropathy · study director
- Ph2NCT05003986 · Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesTravere Therapeutics, Inc. · recruiting · Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy · study director
- Ph3NCT03762850 · A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyTravere Therapeutics, Inc. · completed · Immunoglobulin A Nephropathy · study director
- Ph3NCT03493685 · Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Travere Therapeutics, Inc. · completed · Focal Segmental Glomerulosclerosis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:16 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 267 citationsRCR 30.3
- 199 citationsRCR 23.5
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.J Am Soc Nephrol · 2018153 citationsRCR 7.0
- Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.N Engl J Med · 2023104 citationsRCR 11.5
- Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans.J Hypertens · 200017 citationsRCR 0.6
- Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.J Renin Angiotensin Aldosterone Syst · 20048 citationsRCR 0.2
- Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.Clin J Am Soc Nephrol · 20266 citationsRCR 3.0
- Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment.Int J Clin Pharmacol Ther · 20052 citationsRCR 0.1
- Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial.Clin J Am Soc Nephrol · 2026